SEC filing · 8-K

Regeneron Pharmaceuticals, Inc.: Executive or director change

Regeneron granted one-time 10-year performance share unit awards to its CEO and CSO replacing annual equity awards until 2036.

Filed September 30, 2026

Neutral news

What happened

On September 24, 2026, the Board granted one-time performance share unit awards to CEO Leonard S. Schleifer and CSO George D. Yancopoulos.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Regeneron Pharmaceuticals, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.